Impact of early interferon-β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort
10.1016/j.biopha.2021.112572Biomedicine & Pharmacotherapy 146 (2022): 112572
Funded byThis work was primarily supported by Fundaci ́on SEIMC/GeSIDA (grant number COVID-19/SEIMC-FSG). The funders had no role in study design, data collection, data analysis, data interpretation or writing of the manuscript. Additionally, IJ, JB, JRA, JRB, JC, and JP received funding for research from Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirecci ́on General de Redes y Centros de Investigaci ́on Cooperativa, Ministerio de Ciencia, Innovaci ́on y Universidades, cofinanced by the European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014–2020, through the following networks: Spanish AIDS Research Network (RIS) to IJ [grant number RD16CIII/0002/0006], JB [grant number RD16/0025/0017], and JRA [grant number RD16/0025/0018] and Spanish Network for Research in Infectious Diseases (REIPI) to JRB [grant number RD16/0016/0001], JC [grant number RD16/0016/ 0005], and JP [grant number RD16/0016/0009]. IJ [grant number CB21/13/00091], JB [grant number CB21/13/00044], JRA [grant number CB21/13/00039], JRB [grant number CB21/13/00012], and JC [grant number CB21/13/00009] also received support from the CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovaci ́on, cofinanced by the European Development Regional Fund
SubjectsCOVID-19; Interferon-β; Mortality; SARS-CoV-2; Treatment; Medicina
Rights© 2021 The Author(s)
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
Background: Interferon-β is an attractive drug for repurposing and use in the treatment of COVID-19, based on its in vitro antiviral activity and the encouraging results from clinical trials. The aim of this study was to analyze the impact of early interferon-β treatment in patients admitted with COVID-19 during the first wave of the pandemic. Methods: This post hoc analysis of a COVID-19@Spain multicenter cohort included 3808 consecutive adult patients hospitalized with COVID-19 from 1 January to 17 March 2020. The primary endpoint was 30-day all-cause mortality, and the main exposure of interest was subcutaneous administration of interferon-β, defined as early if started ≤ 3 days from admission. Multivariate logistic and Cox regression analyses were conducted to identify the associations of different variables with receiving early interferon-β therapy and to assess its impact on 30-day mortality. A propensity score was calculated and used to both control for confounders and perform a matched cohort analysis. Results: Overall, 683 patients (17.9%) received early interferon-β therapy. These patients were more severely ill. Adjusted HR for mortality with early interferon-β was 1.03 (95% CI, 0.82–1.30) in the overall cohort, 0.96 (0.82–1.13) in the PS-matched subcohort, and 0.89 (0.60–1.32) when interferon-β treatment was analyzed as a time-dependent variable. Conclusions: In this multicenter cohort of admitted COVID-19 patients, receiving early interferon-β therapy after hospital admission did not show an association with lower mortality. Whether interferon-β might be useful in the earlier stages of the disease or specific subgroups of patients requires further research
Files in this item
Google Scholar:Salto-Alejandre, Sonsoles - Palacios-Baena, Zaira R. - Arribas López, José Ramón - Berenguer Berenguer, Juan - Carratalà, Jordi - Jarrín, Inmaculada - Ryan, Pablo - Miguel-Montero, Marta de - Rodríguez-Baño, Jesús - Pachón, Jerónimo
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: The COVID-19 SEIMC score
HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype Berenguer, Juan; Calleja Panero, José Luis; Montes, María Luisa; Gil, Ángela; Moreno, Ana; Bañares, Rafael; Aldámiz-Echevarría, Teresa; Albillos, Agustín; Téllez, María Jesús; Olveira, Antonio; Domínguez, Lourdes; Fernández, Inmaculada; García-Samaniego, Javier; Polo, Benjamín A.; Álvarez, Beatriz; Ryan, Pablo; Barrio, José; Devesa, María J.; Benítez, Laura; Santos Gil, Ignacio de los; Buey, Luisa García; Sanz, José; Poves, Elvira; Losa, Juan E.; Fernández-Rodríguez, Conrado; Jarrín, Inmaculada; Calvo, María J.; González García, Juan Julián
Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial Diago-Sempere, Elena; Bueno, José Luis; Sancho-López, Aránzazu; Muñez-Rubio, Elena; Torres, Ferrán; Malo de Molina, Rosa; Fernández-Cruz, Ana; Salcedo de Diego, Isabel; Velasco-Iglesias, Ana; Payares-Herrera, Concepción; Casas Flecha, Inmaculada; Avendaño Solá, Cristina; Duarte Palomino, Rafael; Ramos Martínez, Antonio; Ruiz-Antorán, Belén